Drug
Ly4256984
Ly4256984: highest development phase Phase 1, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY4256984 NCT07100119 | Phase 1 | ALS (Amyotrophic Lateral Sclerosis) |
Latest
No recent events.
Follow Ly4256984 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.